Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Edgewise Therapeutics, Inc. Common Stock

EWTX

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Last trade $41.91
Day change -$1.77 (-4.05%)
Day range $41.45 – $44.05
Volume 893,264
Market cap $4.78B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.78B
Price / earnings
4.74×
Price / book
2.93×
Price / sales
—
EV / sales
—
EV / EBITDA
-21.82×

Profitability

Earnings per share
$9.22
Return on assets
56.72%
Return on equity
61.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
12.3×
Quick ratio
12.3×
Cash ratio
0.48×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$202.28M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EWTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$14.57M$14.4M$11.46M$12.39M$9.38M$9.05M$9.2M$9.17M
Research and development$31.58M$47.55M$42.65M$43.59M$37.48M$33.56M$36.76M$36.37M
Total operating expenses$46.14M$61.94M$54.12M$55.98M$46.86M$42.61M$45.96M$45.54M
Operating income-$46.14M-$61.94M-$54.12M-$55.98M-$46.86M-$42.61M-$45.96M-$45.54M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$1.32B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.8M-$39.66M
Income taxes$155.33M$0$0$0$0$0$0$0
Net income$1.17B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.8M-$39.66M
Net income attributable to common shareholders$1.17B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.8M-$39.66M
EBITDA-$45.61M-$61.4M-$53.58M-$55.45M-$46.34M-$42.09M-$45.45M-$44.96M
Basic earnings per share$10.71-$0.53-$0.46-$0.47-$0.39-$0.34-$0.43-$0.42
Diluted earnings per share$9.65-$0.53-$0.46-$0.47-$0.39-$0.34-$0.43-$0.42

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Can BMY Sustain Growth in Its Cardiovascular Franchise?

Bristol Myers Squibb expanded Camzyos' FDA approval to pediatric patients, broadening its addressable market in the obstructive hypertrophic cardiomyopathy space. Camzyos sales surged 61% to $1.1 billion, while Eliquis revenues rose 21% to $13.3 billion in nine months. However, BMY faces competitive pressure from Cytokinetics' newly approved Myqorzo and potential competition from Edgewise Therapeutics, while upcoming patent expirations pose longer-term revenue challenges.

Zacks Investment Research

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?

Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.

Zacks Investment Research

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.

GlobeNewswire Inc.

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Immutrin Ltd, a biotechnology company developing antibody therapy for amyloidosis, has appointed Dr. Robert Blaustein as Chief Medical Officer. Blaustein brings over 15 years of cardiovascular drug development experience from previous roles at Edgewise Therapeutics and Merck. The company has also established a US subsidiary to support planned clinical activities in North America as it advances toward first-in-human studies.

The Motley Fool

Why Edgewise Therapeutics Stock Topped the Market on Tuesday

Edgewise Therapeutics stock rose 2.18% on Tuesday after JPMorgan analyst Tessa Romero raised her price target by $11 per share to $45, maintaining an overweight rating. The upgrade was driven by optimism about the company's pipeline drugs, particularly EDG-7500 for heart disorder treatment and sevasemten for muscular dystrophy, which showed positive long-term study data.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.